Recognition Functions of Pentameric C-Reactive Protein in Cardiovascular Disease

被引:28
|
作者
Agrawal, Alok [1 ]
Gang, Toh B. [1 ]
Rusinol, Antonio E. [1 ]
机构
[1] E Tennessee State Univ, Quillen Dishner Coll Med, Dept Biomed Sci, Johnson City, TN 37614 USA
关键词
LOW-DENSITY-LIPOPROTEIN; FOAM-CELL-FORMATION; ATHEROSCLEROTIC LESIONS; APOPTOTIC CELLS; IMMUNOHISTOCHEMICAL LOCALIZATION; INFARCT SIZE; OXIDIZED LDL; COMPLEMENT; BINDING; MACROPHAGES;
D O I
10.1155/2014/319215
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
C-reactive protein (CRP) performs two recognition functions that are relevant to cardiovascular disease. First, in its native pentameric conformation, CRP recognizes molecules and cells with exposed phosphocholine (PCh) groups, such as microbial pathogens and damaged cells. PCh-containing ligand-bound CRP activates the complement system to destroy the ligand. Thus, the PCh-binding function of CRP is defensive if it occurs on foreign pathogens because it results in the killing of the pathogen via complement activation. On the other hand, the PCh-binding function of CRP is detrimental if it occurs on injured host cells because it causes more damage to the tissue via complement activation; this is how CRP worsens acute myocardial infarction and ischemia/reperfusion injury. Second, in its nonnative pentameric conformation, CRP also recognizes atherogenic low-density lipoprotein (LDL). Recent data suggest that the LDL-binding function of CRP is beneficial because it prevents formation of macrophage foam cells, attenuates inflammatory effects of LDL, inhibits LDL oxidation, and reduces proatherogenic effects of macrophages, raising the possibility that nonnative CRP may show atheroprotective effects in experimental animals. In conclusion, temporarily inhibiting the PCh-binding function of CRP along with facilitating localized presence of nonnative pentameric CRP could be a promising approach to treat atherosclerosis and myocardial infarction. There is no need to stop the biosynthesis of CRP.
引用
收藏
页数:6
相关论文
共 50 条
  • [21] C-reactive protein and cardiovascular disease: Weighing the evidence
    Lowe G.D.O.
    Pepys M.B.
    Current Cardiovascular Risk Reports, 2007, 1 (1) : 72 - 79
  • [22] The role of c-reactive protein in cardiovascular disease risk
    Albert M.A.
    Current Cardiology Reports, 2000, 2 (4) : 274 - 279
  • [23] Cardiovascular disease: Is C-reactive protein the bad guy?
    Ahmed, Mohamed H.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2007, 76 (03) : 472 - 473
  • [24] C-reactive protein and cardiovascular disease: Weighing the evidence
    Lowe G.D.O.
    Pepys M.B.
    Current Atherosclerosis Reports, 2006, 8 (5) : 421 - 428
  • [25] The Role of C-Reactive Protein in Atherosclerotic Cardiovascular Disease: An Overview
    Nakou, Eleni S.
    Liberopoulos, Evangelos N.
    Milionis, Haralampos J.
    Elisaf, Moses S.
    CURRENT VASCULAR PHARMACOLOGY, 2008, 6 (04) : 258 - 270
  • [26] C-reactive protein, inflammatory conditions, and cardiovascular disease risk
    Dhingra, Ravi
    Gona, Philimon
    Nam, Byung-Ho
    D'Agostino, Ralph B.
    Wilson, Peter W. F.
    Benjamin, Emelia J.
    O'Donnell, Christopher J.
    AMERICAN JOURNAL OF MEDICINE, 2007, 120 (12): : 1054 - 1062
  • [27] Impact of C-reactive protein on treatment of patients with cardiovascular disease
    Gortney, Justine Schuller
    Sanders, Rhonda Martin
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2007, 64 (19) : 2009 - 2016
  • [28] C-reactive protein, inflammation, and cardiovascular disease - Clinical update
    Ridker, PM
    TEXAS HEART INSTITUTE JOURNAL, 2005, 32 (03) : 384 - 386
  • [29] C-reactive protein and cardiovascular disease in peritoneal dialysis patients
    Ducloux, D
    Bresson-Vautrin, C
    Kribs, M
    Abdelfatah, A
    Chalopin, JM
    KIDNEY INTERNATIONAL, 2002, 62 (04) : 1417 - 1422
  • [30] High-Sensitivity C-Reactive Protein and Cardiovascular Disease
    Young, Ian
    Rifai, Nader
    CLINICAL CHEMISTRY, 2009, 55 (02) : 201 - 202